Related Experiment Video

Updated: Dec 25, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

87.3K

Low neurodevelopmental performance and behavioural/emotional problems at 24 and 48 months in Brazilian children

Luciana Tovo-Rodrigues1, Marina Xavier Carpena1, Thais Martins-Silva1

  • 1Postgraduate Program in Epidemiology, Universidade Federal de Pelotas, Pelotas, Brazil.

Paediatric and Perinatal Epidemiology
|March 21, 2020
PubMed

Insights

Prenatal acetaminophen exposure was not linked to developmental or behavioral issues in children at 24 and 48 months. This study found no confirmed association between acetaminophen use during pregnancy and later childhood problems.

Area of Science:

  • Pediatric Health
  • Neurodevelopmental Research
  • Prenatal Exposure Studies

Background:

  • Previous research suggests a link between prenatal acetaminophen exposure and developmental/behavioral problems.
  • However, limited studies have specifically examined early-life development and behavioral outcomes.

Purpose of the Study:

  • To investigate the association between prenatal acetaminophen exposure and neurodevelopmental performance at 24 months.
  • To assess the relationship between prenatal acetaminophen exposure and behavioral/emotional problems at 48 months.

Main Methods:

  • Utilized data from the 2004 Pelotas Birth Cohort, a prospective longitudinal study.
  • Neurodevelopment assessed at 24 months using Battelle's Developmental Inventory (BDI).
  • Behavioral/emotional problems evaluated at 48 months using the Child Behaviour Checklist (CBCL), with adjusted analyses for confounding factors.

Main Results:

  • Prenatal acetaminophen exposure showed no statistically significant association with low neurodevelopmental performance at 24 months (BDI).
  • No association was found between prenatal acetaminophen exposure and emotional/behavioral problems at 48 months (CBCL) in adjusted models.

Conclusions:

  • The study could not confirm an association between acetaminophen use during pregnancy and adverse neurodevelopmental or behavioral outcomes at 24 and 48 months.
  • Further research may be needed to fully understand any potential long-term effects, but current findings do not support a link.
Abstract

Keywords:
acetaminophenchild developmentdevelopmentalneurodevelopmental disorderspregnancypsychology

More Related Videos

Moderate Prenatal Alcohol Exposure and Quantification of Social Behavior in Adult Rats11:01

Moderate Prenatal Alcohol Exposure and Quantification of Social Behavior in Adult Rats

Published on: December 14, 2014

10.1K
Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

15.0K

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
656
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
142
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
180
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.7K